FDA OKs Farxiga for Heart Failure With Reduced Ejection Fraction
News Consumer News FDA OKs Farxiga for Heart Failure With Reduced Ejection Fraction WEDNESDAY, May 6, 2020 — The U.S. Food and Drug Administration has granted approval for Farxiga (dapagliflozin) oral tablets to treat adults with heart failure with reduced ejection fraction, the agency announced Tuesday. Farxiga is the first approved sodium-glucose cotransporter 2 inhibitor… Read More »